|
n
|
151,440
|
47,310
|
72,133
|
31,119
|
35
|
843
| |
|
Age, mean (SD) in years
|
66.33 (17.18)
|
51.51 (17.11)
|
74.43 (11.82)
|
70.00 (12.77)
|
67.77 (17.33)
|
69.17 (12.92)
|
< 0.001
|
|
Sex (%)
|
|
Female
|
57,511 (38.0)
|
10,912 (23.1)
|
31,595 (43.8)
|
14,689 (47.2)
|
15 (42.9)
|
300 (35.6)
|
< 0.001
|
|
Male
|
93,929 (62.0)
|
36,398 (76.9)
|
40,538 (56.2)
|
16,430 (52.8)
|
20 (57.1)
|
543 (64.4)
| |
|
Survival, mean (SD) in months
|
65.31 (78.17)
|
38.12 (61.18)
|
81.09 (81.72)
|
70.14 (81.85)
|
74.10 (87.83)
|
57.43 (69.14)
|
< 0.001
|
|
Grade (%)
|
|
B-cell; pre-B; B-precursor
|
7818 (5.2)
|
4899 (10.4)
|
1898 (2.6)
|
1001 (3.2)
|
1 (2.9)
|
19 (2.3)
|
< 0.001
|
|
Moderately differentiated; Grade II
|
33,347 (22.0)
|
5243 (11.1)
|
19,510 (27.0)
|
8384 (26.9)
|
11 (31.4)
|
199 (23.6)
| |
|
NK cell; natural killer cell (1995+)
|
20 (0.0)
|
11 (0.0)
|
4 (0.0)
|
4 (0.0)
|
0 (0.0)
|
1 (0.1)
| |
|
Null cell; non-T-non-B
|
36 (0.0)
|
22 (0.0)
|
10 (0.0)
|
4 (0.0)
|
0 (0.0)
|
0 (0.0)
| |
|
Poorly differentiated; Grade III
|
20,022 (13.2)
|
3458 (7.3)
|
11,114 (15.4)
|
5330 (17.1)
|
3 (8.6)
|
117 (13.9)
| |
|
T-cell
|
709 (0.5)
|
428 (0.9)
|
182 (0.3)
|
96 (0.3)
|
0 (0.0)
|
3 (0.4)
| |
|
Undifferentiated; anaplastic; Grade IV
|
4096 (2.7)
|
1135 (2.4)
|
2002 (2.8)
|
933 (3.0)
|
2 (5.7)
|
24 (2.8)
| |
|
Unknown
|
72,008 (47.5)
|
30,021 (63.5)
|
29,289 (40.6)
|
12,279 (39.5)
|
15 (42.9)
|
404 (47.9)
| |
|
Well differentiated; Grade I
|
13,384 (8.8)
|
2093 (4.4)
|
8124 (11.3)
|
3088 (9.9)
|
3 (8.6)
|
76 (9.0)
| |
|
Laterality (%)
|
|
Bilateral, single primary
|
1198 (0.8)
|
739 (1.6)
|
290 (0.4)
|
160 (0.5)
|
2 (5.7)
|
7 (0.8)
|
< 0.001
|
|
Left—origin of primary
|
20,467 (13.5)
|
5006 (10.6)
|
10,792 (15.0)
|
4542 (14.6)
|
4 (11.4)
|
123 (14.6)
| |
|
Not a paired site
|
104,929 (69.3)
|
35,125 (74.2)
|
48,181 (66.8)
|
21,046 (67.6)
|
23 (65.7)
|
554 (65.7)
| |
|
Only one side—side unspecified
|
331 (0.2)
|
114 (0.2)
|
139 (0.2)
|
74 (0.2)
|
0 (0.0)
|
4 (0.5)
| |
|
Paired site, but no information concerning laterality
|
2177 (1.4)
|
949 (2.0)
|
879 (1.2)
|
326 (1.0)
|
0 (0.0)
|
23 (2.7)
| |
|
Paired site: midline tumour
|
31 (0.0)
|
8 (0.0)
|
15 (0.0)
|
8 (0.0)
|
0 (0.0)
|
0 (0.0)
| |
|
Right—origin of primary
|
22,307 (14.7)
|
5369 (11.3)
|
11,837 (16.4)
|
4963 (15.9)
|
6 (17.1)
|
132 (15.7)
| |
|
Race (%)
|
|
American Indian/Alaska Native
|
738 (0.5)
|
292 (0.6)
|
285 (0.4)
|
148 (0.5)
|
1 (2.9)
|
12 (1.4)
|
< 0.001
|
|
Asian or Pacific Islander
|
7494 (4.9)
|
2074 (4.4)
|
3948 (5.5)
|
1313 (4.2)
|
0 (0.0)
|
159 (18.9)
| |
|
Black
|
19,020 (12.6)
|
8249 (17.4)
|
5647 (7.8)
|
4951 (15.9)
|
10 (28.6)
|
163 (19.3)
| |
|
Unknown
|
711 (0.5)
|
213 (0.5)
|
423 (0.6)
|
68 (0.2)
|
0 (0.0)
|
7 (0.8)
| |
|
White
|
123,477 (81.5)
|
36,482 (77.1)
|
61,830 (85.7)
|
24,639 (79.2)
|
24 (68.6)
|
502 (59.5)
| |
|
Behavior (%)
|
|
Benign
|
1067 (0.7)
|
234 (0.5)
|
497 (0.7)
|
331 (1.1)
|
2 (5.7)
|
3 (0.4)
|
< 0.001
|
|
Borderline malignancy
|
2182 (1.4)
|
525 (1.1)
|
890 (1.2)
|
745 (2.4)
|
0 (0.0)
|
22 (2.6)
| |
|
In situ
|
8110 (5.4)
|
2188 (4.6)
|
4082 (5.7)
|
1796 (5.8)
|
4 (11.4)
|
40 (4.7)
| |
|
Malignant
|
140,081 (92.5)
|
44,363 (93.8)
|
66,664 (92.4)
|
28,247 (90.8)
|
29 (82.9)
|
778 (92.3)
| |
|
Marital status (%)
|
|
Divorced
|
10,617 (7.0)
|
3768 (8.0)
|
4358 (6.0)
|
2424 (7.8)
|
2 (5.7)
|
65 (7.7)
|
< 0.001
|
|
Married
|
64,925 (42.9)
|
12,993 (27.5)
|
35,789 (49.6)
|
15,691 (50.4)
|
17 (48.6)
|
435 (51.6)
| |
|
Separated
|
2043 (1.3)
|
566 (1.2)
|
1036 (1.4)
|
413 (1.3)
|
1 (2.9)
|
27 (3.2)
| |
|
Single
|
34,464 (22.8)
|
23,609 (49.9)
|
7133 (9.9)
|
3607 (11.6)
|
8 (22.9)
|
107 (12.7)
| |
|
Unknown
|
9519 (6.3)
|
2709 (5.7)
|
4562 (6.3)
|
2185 (7.0)
|
0 (0.0)
|
63 (7.5)
| |
|
Unmarried or domestic Partner
|
39 (0.0)
|
31 (0.1)
|
4 (0.0)
|
4 (0.0)
|
0 (0.0)
|
0 (0.0)
| |
|
Widowed
|
29,833 (19.7)
|
3634 (7.7)
|
19,251 (26.7)
|
6795 (21.8)
|
7 (20.0)
|
146 (17.3)
| |
